Search

Your search keyword '"left ventricular ma"' showing total 3 results
Start Over Descriptor "left ventricular ma" Publisher springer science and business media llc
3 results on '"left ventricular ma"'

1. Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease

Author

Valentina Cacciatore, Laura Guarino, Emilio Nardi, Ilenia Calcaterra, Francesco Vaccaro, Santina Cottone, Giulio Geraci, Giuseppe Mulè, Bruno Oddo, Mulè, G., Nardi, E., Guarino, L., Cacciatore, V., Geraci, G., Calcaterra, I., Oddo, B., Vaccaro, F., and Cottone, S.

Subjects
Male, Settore MED/09 - Medicina Interna, Physiology, Blood Pressure, Kidney Function Tests, urologic and male genital diseases, Muscle hypertrophy, chemistry.chemical_compound, Aldosterone, Medicine (all), Confounding, Middle Aged, female genital diseases and pregnancy complications, left ventricular geometry, medicine.anatomical_structure, left ventricular ma, Creatinine, Hypertension, Cardiology, Female, Hypertrophy, Left Ventricular, Waist Circumference, Cardiology and Cardiovascular Medicine, Human, Adult, medicine.medical_specialty, Renal function, Young Adult, Internal medicine, CKD, Internal Medicine, medicine, Humans, Renal Insufficiency, Chronic, Aged, Settore MED/14 - Nefrologia, Kidney Function Test, business.industry, Cardiovascular risk, medicine.disease, Settore MED/11 - Malattie Dell'Apparato Cardiovascolare, Uric Acid, Endocrinology, Blood pressure, chemistry, Ventricle, plasma aldosterone, business, Kidney disease
Abstract

Plasma aldosterone concentrations (PACs) are often increased in the advanced stages of chronic kidney disease (CKD); however, PAC has not been fully investigated in early CKD. Moreover, little is known about the relationship between aldosteronemia and left ventricular (LV) mass in subjects with mild-to-moderate CKD. The study objectives were to analyze PAC, LV mass (LVM), LV geometry and their relationships, in a group of hypertensive patients with stage I-III CKD. One hundred ninety-five hypertensive patients with stage I-III CKD were enrolled and compared with a control group of 82 hypertensive patients without renal dysfunction. LVM was higher in subjects with CKD than in the control group and increased progressively with advancing stages of CKD (P=0.004). A similar trend was observed for PAC (P

Published
2015

2. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives?

Author

Carla Sala, Cesare Cuspidi, Stefano Meani, Giuseppe Mancia, Valentina Giudici, Francesca Negri, Alberto Zanchetti, Cristiana Valerio, Cuspidi, C, Meani, S, Negri, F, Giudici, V, Valerio, C, Sala, C, Zanchetti, A, and Mancia, G

Subjects
Adult, Male, arterial hypertension, obesity, medicine.medical_specialty, Adolescent, Body Surface Area, Heart Ventricles, Population, Blood Pressure, Overweight, Left ventricular hypertrophy, Sensitivity and Specificity, Young Adult, Predictive Value of Tests, Internal medicine, Prevalence, Internal Medicine, medicine, Humans, Registries, education, Aged, Aged, 80 and over, Echocardiography, Doppler, Pulsed, Body surface area, education.field_of_study, business.industry, Models, Cardiovascular, Blood Pressure Determination, Middle Aged, Sphygmomanometers, medicine.disease, Obesity, Body Height, Endocrinology, Blood pressure, indexation of ventricular mass, left ventricular ma, Hypertension, Cohort, Cardiology, Female, Hypertrophy, Left Ventricular, medicine.symptom, business, Body mass index
Abstract

Whether left ventricular mass (LVM) should be normalized to different indexes in relation to body size is still debated. We sought to evaluate the prevalence of left ventricular hypertrophy (LVH) defined by different indexation criteria in a cohort of hypertensive subjects categorized according to body mass index (BMI). A total of 2213 essential hypertensive subjects included in the Evaluation of Target Organ Damage in Hypertension (ETODH) were divided in three groups according to BMI thresholds (25, 25-29.9 andor=30 kg m(-2)). All patients underwent extensive investigations including quantitative echocardiography. LVH was defined as an LVM index equal to or higher than (1) 125 g m(-2) in men and 110 g m(-2) in women, (2) 51 g m(-2.7) in men and 47 g m(-2.7) in women. Overall, 687 out of 2213 patients (31.0%) were found to have LVH when LVM was indexed to body surface area (BSA) and 1030 (46.5%) when indexed to height(2.7). A total of 845 patients (38.2%) had normal BMI, 954 patients (43.1%) were overweight and 414 (18.7%) were obese. Prevalence rates of LVH in the three groups were 25.1, 31.6, 41.2% by indexation to BSA and 29.9, 50.5, 71.8% by indexation to height(2.7), respectively. LVM indexed to BSA markedly underestimates LVH prevalence in obese as well as overweight hypertensive patients. To avoid a systematic misclassification of cardiovascular risk, LVM should be routinely indexed to height(2.7) in overweight and obese patients representing a large percentage of the hypertensive population.

Published
2009

3. Effects of losartan on hypertension and left ventricular mass: a long-term study

Author

Diana Iarussi, Domenico Galzerano, Giuseppe Limongelli, Aldo Iacono, M A Tedesco, G. Di Salvo, D Aquino, Gennaro Ratti, S. Mennella, Tedesco, Ma, Ratti, G, Aquino, D, Caccavale, A, Limongelli, Giuseppe, and DI SALVO, Giovanni

Subjects
Adult, Male, medicine.medical_specialty, Left ventricular ma, Diastole, Angiotensin II receptor antagonist, Essential hypertension, Losartan, Left ventricular mass, Hydrochlorothiazide, Double-Blind Method, Internal medicine, Internal Medicine, Humans, Medicine, Antihypertensive Agents, Aged, business.industry, Female, Hypertension, Hypertrophy, Left Ventricular, Middle Aged, Hypertrophy, medicine.disease, Left Ventricular, Surgery, Blood pressure, Tolerability, Blood chemistry, Cardiology, business, medicine.drug
Abstract

This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension. The study included 77 hypertensive patients who were randomised at baseline to 22 months double-blind once-daily treatment with losartan 50 mg (L group n = 44 patients, mean age 54+/-9 years) or hydrochlorothiazide 25 mg (HCTZ group, n = 33 patients, mean age 56+/-7 years). Routine haematology, blood chemistry, standard electrocardiography, echocardiography and ambulatory non-invasive 24-h blood pressure (BP) monitoring were performed at baseline and after 10 and 22 months. The results showed good tolerability and a significant mean systolic and diastolic BP reduction in all groups (L group: 22 mm Hg and 11 mm Hg; HCTZ group: 11 mm Hg and 7 mm Hg, respectively for systolic and diastolic mean BP). Moreover, a remarkable reduction in left ventricular mass index was reached after 10 and 22 months only in the L group (L group: delta = -11 g/m2, P

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results